Daiichi Sankyo Co Limited Sponsored Adr News, Daiichi Sankyo Co Limited Sponsored Adr Quote, DSNKY Quote

Daiichi Sankyo Co Limited Sponsored Adr (OP:DSNKY) Delayed: 17.55 +0.67 (3.97%)

Prev. Close

$16.88

Today 6M 1Y 5Y

Open

$17.59

52 Wk High

$26.24

52 Wk Low

$18.86

Day High

$17.88

Day Low

$17.47

P/E

N/A

EPS

$0.00

Volume

106,833

Friends, Peers and Foes (?): 4568:JP, AZN, MRK, CGEN, CW9 (more...)

ALERTS | RSS

Aug 6, 2026 06:31 AM Daiichi Sankyo Company, Limited (4568:JP) (DSNKY) PT Raised to JPY4,900 at Citi
Aug 4, 2026 06:59 AM Daiichi Sankyo Company, Limited (4568:JP) (DSNKY) PT Lowered to JPY4,300 at Macquarie
Jul 31, 2026 04:30 AM Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results
Jul 31, 2026 02:47 AM Jefferies Downgrades Daiichi Sankyo Company, Limited (4568:JP) (DSNKY) to Hold
Jul 31, 2026 02:30 AM Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy
Jul 24, 2026 07:00 AM EU panel backs Enhertu plus pertuzumab for HER2+ breast cancer
Jul 24, 2026 07:00 AM Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer
Jun 29, 2026 02:30 AM Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors
Jun 26, 2026 07:01 AM EU panel backs Datroway for metastatic breast cancer patients
Jun 26, 2026 07:00 AM Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy

Entities mentioned with DSNKY

View All Entities